Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.

Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Leal TA, Du L, Hernandez J, Huang V, Blumenschein GR, Waqar SN, Patel SP, Nieva J, Oxnard GR, Sanborn RE, Shaffer T, Garg K, Holzhausen A, Harrow K, Liang C, Lim LP, Li M, Lovly CM
J Thorac Oncol. 2019 14 (11): 1901-1911

PMID: 31446141 · PMCID: PMC6823161 · DOI:10.1016/j.jtho.2019.08.003

MeSH Terms (18)

Adult Aged Aged, 80 and over Anaplastic Lymphoma Kinase Carcinoma, Non-Small-Cell Lung Circulating Tumor DNA Drug Resistance, Neoplasm Female Humans Lung Neoplasms Male Middle Aged Mutation Oncogene Proteins, Fusion Piperazines Prognosis Protein Kinase Inhibitors Pyridazines

Connections (1)

This publication is referenced by other Labnodes entities:

Links